Sotyktu (deucravacitinib) Awaits FDA Decision by March 6 for Adults with Active Psoriatic Arthritis
The FDA approved Sotyktu (deucravacitinib) on March 6, 2026, for adults with active psoriatic arthritis based on positive phase 3 trial results.
Read More